Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01690403 · ClinicalTrials.gov registry record · Phase 1
Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01690403 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 25 participants.
The verdict
NCT01690403, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Primary Objective: \- To evaluate the effect of single and repeated administration of rifapentine given as daily or weekly regimen on steady-state pharmacokinetic parameters of efavirenz, emtricitabine and tenofovir given as a fixed dose combination (ATRIPLA™ ). Secondary Objective: \- To evaluate the safety and tolerability of concomitant administration of rifapentine and ATRIPLA™ given to HIV+ patients
Interventions
- DRUG rifapentine (M000473)
- DRUG EFZ EMT TDF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01690403
The ClinicalTrials.gov registry entry for NCT01690403 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rifapentine (M000473) is the first listed.
NCT01690403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01690403 about?
NCT01690403 is a clinical study titled "Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients". Primary Objective: \- To evaluate the effect of single and repeated administration of rifapentine given as daily or weekly regimen on steady-state pharmacokinetic parameters of efavirenz, emtricitabine and tenofovir given as a fixed dose combination (ATRIPLA™ ). Secondary Objective: \- To evaluat...
What is the current status of trial NCT01690403?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-12. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01690403?
The interventions under investigation include: rifapentine (M000473) (DRUG), EFZ EMT TDF (DRUG).
Who is sponsoring clinical trial NCT01690403?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.